LY6K and esophageal squamous cell carcinoma: In patients with esophageal squamous cell carcinoma treated with HLA-A24 binding peptides from TTK protein kinase, LY6K, and IMP3, OS was longer, but not significantly, in patients who were HLA-A*24:02 positive (A24[+]) compared with those who were HLA-A*24:02 negative (A24[–]); median survival time was 4.6 versus 2.6 months (p = 0.121) [29].